Last Updated: August 15, 2026

Details for Patent: 8,207,127


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,207,127
Title:Compounds for enzyme inhibition
Abstract:Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Inventor(s):Mark S. Smyth, Guy J. Laidig
Assignee: Onyx Technologies USA Inc , Onyx Therapeutics Inc
Application Number:US13/334,544
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,207,127
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 8,207,127

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,207,127

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1781688 ⤷  Start Trial PA2016010 Lithuania ⤷  Start Trial
European Patent Office 1781688 ⤷  Start Trial 93015 Luxembourg ⤷  Start Trial
European Patent Office 1781688 ⤷  Start Trial CA 2016 00014 Denmark ⤷  Start Trial
European Patent Office 1781688 ⤷  Start Trial 300805 Netherlands ⤷  Start Trial
European Patent Office 1781688 ⤷  Start Trial 16C0017 France ⤷  Start Trial
European Patent Office 1781688 ⤷  Start Trial C20160008 00189 Estonia ⤷  Start Trial
European Patent Office 1781688 ⤷  Start Trial 1690013-6 Sweden ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.